Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | GHSR | Q92847 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | HTR3A | P46098 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quazepam SCHEMBL29504 | 0.87 | OPRK1 (0.58) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Quazepam SCHEMBL29534458 | 0.87 | OPRK1 (0.58) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| SCHEMBL25176170 | 0.87 | OPRK1 (0.68) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| SCHEMBL7433919 | 0.87 | OPRK1 (0.77) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Halazepam SCHEMBL29375979 | 0.87 | OPRK1 (1.00) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Halazepam SCHEMBL78995 | 0.87 | OPRK1 (1.00) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Flurazepam SCHEMBL1955159 | 0.86 | OPRK1 (0.81) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Quazepam SCHEMBL21647120 | 0.86 | OPRK1 (0.57) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Desalkylflurazepam SCHEMBL8124276 | 0.86 | OPRK1 (0.76) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Desalkylflurazepam SCHEMBL31365163 | 0.86 | OPRK1 (0.76) | OPRK1NR1I2ADORA3OPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6048857-A | TRIFLUOROBENZODIAZEPINE | ELLINWOOD JR EVERETT H (US) | 2000-04-11 | — | — | US | claimed |
| EP-0428272-A2 | Trifluorobenzodiazepine compounds for use in therapy by intraoral administration | Ellinwood, Everett Hews (US) | 1991-05-22 | — | — | EP | claimed |
| US-4155904-A | Process for the preparation of 1,4-benzo-diazepines and 1,4-benzodiazepinones | SCHERING CORPORATION (US) | 1979-05-22 | — | — | US | claimed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20210061873-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20190161529-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2019-05-30 | — | — | US | disclosed |
| US-20090069267-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2009-03-12 | — | — | US | disclosed |
| US-20090069267-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2009-03-12 | — | — | US | disclosed |
| JP-2007254392-A | METHOD FOR PRODUCING OXOQUAZEPAM | KONICA MINOLTA CHEMICAL CO LTD | 2007-10-04 | — | — | JP | disclosed |
| US-6313176-B1 | SELECTING AN IRREVERSIBLE ENZYME INHIBITOR AS A MEDICAMENT THAT IS METABOLIZED INTO AN UNWANTED OR ADVERSIVE METABOLITE; PLACING IRREVERSIBLE ENZYME INHIBITOR IN A SUITABLE FORMULATION; ADMINISTERING FORMULATION FOR THERAPY | ELLINWOOD JR EVERETT J (US) | 2001-11-06 | — | — | US | disclosed |
| US-6140323-A | SELECTING DRUG; PLACING FOR INHALATION OR SKIN ADMINISTRATION FORMAULATION; ADMINISTERING FORMULATION SO AS TO BYPASS GASTROINTESTINAL ABSORPTION AND PORTAL VEIN ENTRY TO LIVER TO DECREASE FORMATION OF UNWANTED METABOLITE | ELLINWOOD JR EVERETT H (US) | 2000-10-31 | — | — | US | disclosed |
| US-6048857-A | TRIFLUOROBENZODIAZEPINE | ELLINWOOD JR EVERETT H (US) | 2000-04-11 | — | — | US | disclosed |
| US-4997771-A | Method for measuring the BZ-1 receptor binding activity in a test sample or test compound | SCHERING CORPORATION (US) | 1991-03-05 | — | — | US | disclosed |
| US-4155904-A | Process for the preparation of 1,4-benzo-diazepines and 1,4-benzodiazepinones | SCHERING CORPORATION (US) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069267-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | INA, BDNF, PMP22 | OPRK1 255/4885NR1I2 3623/4885ADORA3 917/4885 |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | OPRK1 225/4885NR1I2 2295/4885ADORA3 553/4885 |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
| US-20210061873-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
| US-20190161529-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | OPRK1 415/4885NR1I2 3135/4885ADORA3 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.